PTN — Palatin Technologies Share News
0.000.00%
Last trade - 00:00- $9.10m
- $1.61m
- $13.19m
Palatin slides on 1-for-25 reverse stock split plan
Brief: Palatin Technologies announces intent to effect reverse stock split
Brief: Palatin Technologies reports positive interim analysis in Phase 3 pivotal study of Pl9643 in patients with dry eye disease
Brief: Palatin Technologies Inc Says Preliminary Q4 Vyleesi Net Product Revenue Increased 225% Over Prior Quarter
Brief: Palatin Reports Third Quarter Fiscal Year 2022 Financial Results And Provides Corporate Update
Brief: Palatin Reports Second Quarter Fiscal Year 2022 Financial Results
Brief: Palatin Technologies Inc Files For Mixed Shelf Of Up To $100 Million
Brief: Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease
Brief: Palatin Reports First Quarter Fiscal Year 2022 Results And Provides Corporate Update
Brief: Palatin Reports Fourth Quarter And Full Year Fiscal Year 2021 Financial Results
Brief: Palatin Announces Presentation Of Positive Protective Effects Of PL8331 And PL9654 On Retinal Inflammation At 2021 American Society Of Retina Specialists Annual Meeting
U.S. STOCKS ON THE MOVE-Qorvo, Moderna, Fox, Marin Software, Morgan Stanley
U.S. STOCKS ON THE MOVE-Bsquare, Doximity, Enerpac Tool
U.S. STOCKS ON THE MOVE-Gold miners, Purple Innovation, Scientific Games
Palatin Technologies rises on positive FDA meeting for eye disease drug
Brief: Palatin Announces Positive End-Of-Phase 2 Meeting With FDA On Pl9643 For The Treatment Of Dry Eye Disease
Brief: Palatin Announces Adjournment Of Annual Meeting Of Stockholders
Brief: Palatin Reports Q3 Loss Per Share Of $0.02
Brief: Palatin Announces U.S. Patent Term Extension For Vyleesi® (Bremelanotide Injection)